Globus Medical, Inc. (NYSE: GMED) is a Healthcare company (Medical - Devices) with a market capitalization of $9.3B. The Maz Rating grades it against the other companies in its sector.
Globus Medical, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $69.99, Globus Medical, Inc. trades at 17.0x trailing earnings, 3.0x sales and 2.0x book value, with an EV/EBITDA of 9.1. Over the last twelve months it generated about $3.1B of revenue and $546M of net income. It runs a gross margin of 70.1%, an operating margin of 22.1% and a net margin of 17.8%. It shows return on equity of 11.8%, return on invested capital of 10.9% and a free cash flow yield of 8.1%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 4.30. Over the past 52 weeks the share price ranged from $69.49 to $101.40, with a beta of 0.96.
Globus Medical, Inc. does not currently pay a dividend.
37 Wall Street analyst ratings cover the stock: 26 Buy, 10 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extensive portfolio includes a variety of spinal products. These encompass traditional fusion implants like pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices, all designed to treat conditions such as degenerative diseases, deformities, tumors, and trauma. Furthermore, they offer advanced motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices. The company also provides interventional pain management options for vertebral compression fractures, alongside a selection of regenerative biologic products such as allografts and synthetic alternatives. Beyond spinal care, Globus Medical manufactures solutions for orthopedic trauma, featuring products like fracture plates, compression screws, intramedullary nails, and external fixation systems. They also specialize in hip and knee joint reconstruction, offering modular hip stems, acetabular cups, and various knee arthroplasty implants, including posterior stabilizing and cruciate retaining designs. Additionally, the company engages in the distribution of human cell, tissue, and other cellular and tissue-based products. Established in 2003, Globus Medical, Inc. maintains its corporate headquarters in Audubon, Pennsylvania.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
Yes. As of September 2026, Globus Medical, Inc. (GMED) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 8.28% / 30% · Interest income / Revenue 1.10% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 4.92% / 33% · Receivables / Mkt Cap (36m) 6.88% / 49% · Interest income / Revenue 1.10% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 4.92% / 33.33% · Receivables / Mkt Cap (24m) 6.88% / 33.33% · Interest income / Revenue 1.10% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.94% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 10.6% / 33.33% · Receivables / Avg Assets (4Q) 13.5% / 33.33% · Interest income / Revenue 1.10% / 5% | Pass |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 9.36% / 33.33% · (Cash+Recv) / Total Assets 22.5% / 33.33% · Interest income / Revenue 1.10% / 5% | Pass |
Yes. As of September 2026, Globus Medical, Inc. (GMED) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
Yes. Globus Medical, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 1.10% of each dividend: Globus Medical, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.